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Abstract
Background: Genomics tools, particularly DNA microarrays, have found application in a number of areas
including gene discovery and disease characterization. Despite the vast utility of these tools, little work has
been done to explore the basis of distinct cellular properties, especially those important to biotechnology
such as growth. And so, with the intent of engineering cell lines by manipulating the expression of these
genes, anchorage-independent and anchorage-dependent HeLa cells, displaying markedly different growth
characteristics, were analyzed using DNA microarrays.
Results: Two genes, cyclin-dependent kinase like 3 (cdkl3) and cytochrome c oxidase subunit (cox15),
were up-regulated in the faster growing, anchorage-independent (suspension) HeLa cells relative to the
slower growing, anchorage-dependent (attached) HeLa cells. Enhanced expression of either gene in the
attached HeLa cells resulted in elevated cell proliferation, though insertion of cdkl3 had a greater impact
than that of cox15. Moreover, flow cytometric analysis indicated that cells with an insert of cdkl3 were able
to transition from the G0/G1 phases to the S phase faster than control cells. In turn, expression of cox15
was seen to increase the maximum viable cell numbers achieved relative to the control, and to a greater
extent than cdkl3. Quantitatively similar results were obtained with two Human Embryonic Kidney-293
(HEK-293) cell lines and a Chinese Hamster Ovary (CHO) cell line. Additionally, HEK-293 cells secreting
adipocyte complement-related protein of 30 kDa (acrp30) exhibited a slight increase in specific protein
production and higher total protein production in response to the insertion of either cdkl3 or cox15.
Conclusion: These results are consistent with previous studies on the functionalities of cdkl3 and cox15.
For instance, the effect of cdkl3 on cell growth is consistent with its homology to the cdk3 gene which is
involved in G1 to S phase transition. Likewise, the increase in cell viability due to cox15 expression is
consistent with its role in oxidative phosphorylation as an assembly factor for cytochrome c oxidase and
its involvement removing apoptosis-inducing oxygen radicals. Collectively, the present study illustrates the
potential of using microarray technology to identify genes influential to specific cellular processes with the
possibility of engineering cell lines as desired to meet production needs.
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Background
The properties of a cell line being used to produce thera-
peutic or diagnostic compounds are vital elements in
designing a production process [1-3]. Such properties
include: nutritional requirements, adhesion capabilities,
glycosylation capabilities, and cellular response to stimuli
[1,2]. Perhaps one of the most important cellular proper-
ties is proliferation, referring to the rate at which cells
grow and divide by passing through the different cell cycle
phases [3,4].
The ability to alter specific properties of a cell line would
undoubtedly find application in the field of biotechnol-
ogy. Currently, protocols and technical notes are readily
available to adapt specific cell lines to make them more
suitable for a particular process. These procedures have
focused primarily on screening cell populations to iden-
tify and subsequently select cells with the desired feature
[3-5]. Less emphasis has been placed on either identifying
how a particular adaptation occurs or the ability to engi-
neer the desired modification directly into the cell lines.
Previous studies exploring proliferation have examined
the roles of various genes and/or chemicals regulating the
cell cycle in hopes of indirectly stimulating cellular
growth [6,7]. For example, it was shown that transfection
of the gene c-myc, a proto-oncogene that encodes a tran-
scription factor, can enhance the growth rate of Chinese
Hamster Ovary (CHO) cells [8]. Other studies have
focused on deciphering the sequence of events necessary
for cells to complete the cell cycle by targeting specific
genes [1,9]. It has been found that certain proteins are
necessary for cells to maintain viability and/or function
such as growth factors and stress sensors [10]. Some stud-
ies have identified groups or families of proteins that play
important roles maintaining cellular function such as
members of the serine/threonine protein kinase family;
essential for phase transitions of the cell cycle [10]. Based
on this, a number of studies have explored what other
proteins associate with members of this kinase family
such as cyclins, inhibitors, and ubiquitin [4,10]. However,
the complexity of the cell cycle has limited the way in
which mammalian cells can be manipulated to increase
their growth.
In the present study, complementary DNA (cDNA) micro-
arrays were used to identify genes potentially influencing
cellular growth by comparing a slow growing, anchorage-
dependent (attached) cell line to a fast growing, anchor-
age-independent (suspension) cell line. Both cell lines
were HeLa cell lines [11]. Microarray data were probed for
differentially expressed genes using clustering algorithms
and proposed functionalities. Two genes, cdkl3 [GenBank:
NM016508] and cox15  [GenBank: NM078470], had
higher expression in the fast growing, suspension HeLa
cells than in the slow growing, attached HeLa cells. The
cDNA for both genes were transfected into a number of
cell lines including Human Embryonic Kidney-293 (HEK-
293), CHO, and Madin-Darby Canine Kidney (MDCK).
The growth characteristics of these cell lines were moni-
tored along with recombinant protein production levels
in the HEK-293 ACRP30 (adipocyte complement-related
protein of 30 kDa) cell line using ELISA. Further character-
ization of the transfected cell physiology was performed
using flow cytometry analysis.
Results
1. Growth of HeLa cells in bioreactors
The attached and suspension HeLa cell lines were grown
in bioreactors in three independent experiments using the
same media and culture environment. The attached HeLa
cells had to be grown using microarriers [12]. The meas-
ured viable cell densities for both cells lines are shown in
Figure 1. The suspension HeLa cells grew at a maximum
specific growth rate of 0.038 ± 0.002 h-1, 40% higher than
the attached HeLa cells which grew at a maximum specific
growth rate of 0.027 ± 0.001 h-1. The suspension HeLa
cells achieved a maximum viable cell density of about 3.5
× 106 cells/mL, twice the maximum viable cell density
obtained for the attached HeLa cells. The overall viability
for each cell line was above 90% until the stationary phase
of growth was reached.
2. Comparison of gene transcription levels between 
suspension and attached HeLa cells
Samples for microarray analysis were taken at the same
growth phases from each bioreactor, at regular intervals.
Imaging software was used to determine which compari-
sons exhibited the most significant differences between
the two cell lines and had the highest levels of overall tran-
Growth of suspension and attached HeLa cells in bioreactors  under batch conditions Figure 1
Growth of suspension and attached HeLa cells in bioreactors 
under batch conditions. Attached HeLa cells were grown on 
Cytodex 3 microcarriers.
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scriptional activity. Samples from the middle exponential
growth phase, corresponding to the maximum specific
growth rates, were found to meet these criteria. This infor-
mation was deciphered by examining scanned images of
hybridized microarrays using GenePix, a visualization
software program.
Analysis of the hybridized cDNA microarrays began with
quality control (i.e. removing spots of poor signal) and
continued with implementation of total intensity normal-
ization [13,14]. The data were filtered by removing genes
lacking consistency between slides in terms of how close
the expression ratio from any one slide was to the median
expression ratio calculated from all of the slides. The data
were also screened for genes with expression ratios from
the slides in the same direction (i.e. either upregulated or
downregulated across all of the slides).
Using clustering algorithms, the genes were organized
into groups [14,15]. Principle component analysis (PCA)
and gap statistic were used to estimate the number and
size of groups inherently present in the data. Results of
these algorithms indicated groups of 8, 9, 13, or 14 were
likely to form. With this information, self-organizing
maps (SOMs) and hierarchical clustering were then
applied to the data to segregate the genes into distinct
groups. These clusters were probed to identify subsets of
genes with relevance to cellular growth based on known
or proposed functionalities related to cell cycle regulation,
apoptosis, and/or signal transduction. Genes that could
be categorized in this manner were then interrogated fur-
ther based on the level of differential expression with a
sampling of the results shown in Table 1. The ratios listed
in Table 1 were determined from a sample size of at least
12; based on the number of spots per slide and the
number of slides analyzed. Of the genes listed, cdkl3 [Gen-
Bank: NM016508] and cox15  [GenBank: NM078470]
were selected for further analysis. As shown in Figure 2,
both cdkl3 and cox15 had expression levels greater than 1,
indicating higher expression in the suspension HeLa cell
line than in the attached HeLa cell line.
3. Verification of microarray results
As can be seen in Table 1 and Figure 2, the expression
ratios of both cdkl3 and cox15 varied over the different
samples, establishing the need to verify these results. For
this purpose, a series of RT-PCR experiments were con-
ducted, the results of which are shown in Table 2 along
with two controls,gapd and pgk1. The findings in the Table
demonstrate the expression levels are consistent between
the microarray data and the RT-PCR experiments.
4. Enhanced expression of cdkl3 and cox15 in attached 
HeLa cells
To evaluate the impact of these two genes in cell culture,
DNA plasmids containing either cdkl3 or cox15 were trans-
fected into the attached HeLa cells. Cells transfected with
only blank plasmids (i.e. containing neither cdkl3  nor
cox15) served as the control. Each plasmid also contained
the neomycin gene allowing cells to be selected based on
resistance to geneticin. A number of clones were selected
in this manner over the course of 1–2 weeks (post-trans-
fection) and then assayed for expression of the translated
protein using western blots. Figure 3 illustrates the protein
expression of cells that have gone through this selection
process. These blots indicate cells transfected with either
cdkl3 or cox15 had significantly higher protein levels than
the control cells. It should be noted that when the selec-
tion marker is not present in the culture media, these cell
lines return to normal protein production levels within 5–
6 passages.
The growth profiles/characteristics of the attached HeLa
cells transfected with cdkl3, cox15, or a blank plasmid are
summarized in Table 3. All three cell lines were grown on
microcarriers in 250 mL spinner flasks. The maximum
specific growth rates, determined in three independent
experiments, revealed that the attached HeLa cells trans-
Table 1: Gene names and maximum/minimum expression ratios for differentially expressed genes identified following normalization 
and application of clustering algorithms. Expression ratios are of the form: suspension HeLa/attached HeLa
Gene Symbol Gene Name Maximum Expression Ratio Minimum Expression Ratio
cdkl3 cyclin-dependent kinase-like 3 3.32 1.76
cox15 cytochrome c oxidase assembly protein 3.87 1.95
agpat2 1-acylglycerol-3-phosphate O-acyltransferase 2 3.13 1.64
fgf7 Fibroblast growth factor 7 3.50 1.75
dtymk deoxythymidylate kinase (thymidylate kinase) 4.05 1.92
arhf ras homolog gene family f 2.95 1.70
plagl1 pleiomorphic adenoma gene-like 1 0.04 0.02
tial1 cytotoxic granule-associated RNA binding protein-like 
1
0.68 0.14
Note: Each cDNA slide analyzed had at least 3 spots for each of the genes listed above. Analysis of 4 slides translated to a total of at least 12 ratios 
for each gene. Both the maximum and the minimum expression ratios per gene were determined from these 12 ratios (i.e. sample size).BMC Biotechnology 2007, 7:71 http://www.biomedcentral.com/1472-6750/7/71
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fected with a plasmid containing either cdkl3  or  cox15
grew faster than the control cells. Cells expressing cdkl3
had a maximum specific growth rate 20% greater than the
control cells while the cells expressing cox15 had a maxi-
mum specific growth rate 15% greater than the control
cells. Using a t-test, it was determined that the differences
in maximum specific growth rates between treated and
control cells were statistically significant for α-values, also
referred to as risk level (i.e. the chance associated with
finding a statistically significant difference between means
when there is none) as low as 0.005. It was also observed
that the duration of the lag phase in cells expressing either
cdkl3 or cox15 was 5 – 8% shorter than that of the control
cells.
Cells expressing cox15 were also able to achieve a maxi-
mum viable cell density 11% higher than the control cells
whereas cells expressing cdkl3 achieved a maximum viable
cell density equivalent to the control cells (Table 3). The
difference between cells expressing cox15 and control cells
were statistically significant for α-values as low as 0.005.
Similar results, in terms of growth rates and cell densities,
were obtained when these cell lines were grown in T-
flasks. No additive effects were observed when both genes
were simultaneously expressed (data not shown).
5. Gene sequence homology and enhanced expression of 
cdkl3 and cox15 in other cell lines
Using two online databases, Harvester and GenBank, the
nucleotide sequences for both cdkl3 and cox15 were deter-
mined [16,17]. Sequence analysis was performed to quan-
tify homology between varying species. For the cdkl3 gene,
the following were determined: 94% similarity with Canis
familiaris  (dog), 83% similarity with Rattus norvegicus
(rat), and 90% similarity with Mus musculus (mouse).
Slightly less similar was the cox15 gene with 87% similar-
ity to Canis familiaris (dog), 86% similarity to Rattus nor-
vegicus (rat), and 86% similarity to Mus musculus (mouse).
Based on these results, three additional cell lines, HEK-
293, CHO, and MDCK were chosen for investigation [18].
The HEK-293 cells were selected to investigate whether or
not the genes identified using HeLa cells had functionality
in other human-derived cell lines. With significant
homology between the two rodent species in terms of
gene transcripts, CHO cells were chosen due to their wide-
spread use in commercial applications [19]. However,
without a central database detailing the sequence of the
CHO genome, the existence of homologs for either cdkl3
or cox15 could not be verified in that species. The canine
cell line selected, MDCK, is commonly used in the pro-
duction of vaccines [19].
When grown under the same spinner flask conditions pre-
viously described, two different types of HEK-293 cells
(HEK-293 and HEK-293 ACRP30) expressing either cdkl3
or cox15 grew faster than the control cells (Table 3). The
maximum specific growth rate of the HEK-293 cells
expressing cdkl3 was 19% greater than the control cells; a
value statistically significant for α-values as low 0.005.
Similarly, the maximum specific growth rate of the HEK-
293 cells expressing cox15 was 13% greater than the con-
trol cells; a value statistically significant for α-values as
low 0.01. Cells expressing cox15 grew to a maximum via-
ble cell density 9% higher than the control cells; statisti-
cally significant for α-values as low 0.005.
HEK-293 ACRP30 cells expressing cdkl3 had a maximum
specific growth rate 16% higher than the control cells
(Table 3); significant for α-values as low 0.005. These cells
Table 2: Median expression levels for specific genes as determined by cDNA microarrays and RT-PCR. Expression ratios are of the 
form: suspension HeLa/attached HeLa
Gene Symbol Gene Name cDNA microarrays RT-PCR
cdkl3 cyclin-dependent kinase-like 3 2.74 2.6 ± 0.2
cox15 cytochrome c oxidase assembly protein 3.01 3.4 ± 0.3
gapd Glyceraldehyde-3-phosphate dehydrogenase 1.03 1.2 ± 0.1
pgk1 Phosphoglycerate kinase 1 0.98 1.0 ± 0.1
Median expression ratios for cdkl3 and cox15 from four dif- ferent spotted cDNA microarray slides Figure 2
Median expression ratios for cdkl3 and cox15 from four dif-
ferent spotted cDNA microarray slides. The median expres-
sion ratio is calculated from 3 or more gene-specific spots on 
a single slide. The error bars indicate the range in expression 
ratios observed for a given slide.
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expressing cox15 also had a maximum specific growth rate
higher than the control cells, by approximately 14%; sta-
tistically significant for α-values as low 0.001. The HEK-
293 ACRP30 cells achieved a maximum viable cell density
8% greater than the control cells; statistically significant
for α-values as low 0.01.
CHO cells with inserts of either cdkl3 or cox15 were also
found to grow faster than control cells, as shown in Table
3. CHO cells expressing cdkl3 had a maximum specific
growth rate 9% higher than the control cells; a value sta-
tistically significant for α-values as low 0.005. CHO cells
expressing cox15 had a maximum specific growth rate 5%
higher than the control cells; statistically significant for α-
values as low 0.025. In addition, cells expressing either
cdkl3 or cox15 achieved maximum viable cell densities 5%
(α-value ≥ 0.005) or 7% (α-value ≥ 0.001) greater than the
control cells, respectively. In contrast, MDCK cells with
inserts of either cdkl3 or cox15 did not exhibit differences
in terms of growth rates or maximum viable cell densities,
as shown in Table 3.
6. Examining cell proliferation using flow cytometry and 
ELISA
In order to evaluate the effects of enhanced expression of
either cdkl3 or cox15 on cell cycle, analysis of cell cycle
progression was performed using flow cytometry. The cell
line exhibiting the greatest effects of enhanced expression
of either cdkl3 or cox15 was the attached HeLa cell line. In
this assay, cells were initially synchronized and then
grown up until late into the exponential phase. Cells with
enhanced expression of either cdkl3 or cox15, shown in
Figure 4, illustrated a lower percentage of cells in the GO-
G1 phases and a higher percentage in the S phase com-
pared to control cells. The percentage of cells in the G2-M
phases was similar between the three cell lines.
Table 3: Growth-related data for varying cell lines grown in spinner flasks
Cell Type Cell line Maximum growth rate during the exponential growth phase (hours-1) from 3 different runs Maximum viable cell 
density (106 cells/mL)
Run 1 Run 2 Run 3 Average Change vs. Control (%)
HeLa control 0.027 0.026 0.026 1.49 ± 0.03
+ cdkl3 0.031 0.032 0.032 20 1.53 ± 0.03
+ cox15 0.030 0.030 0.031 15 1.66 ± 0.02
HEK-293 control 0.030 0.030 0.032 1.98 ± 0.02
+ cdkl3 0.035 0.037 0.037 19 2.04 ± 0.04
+ cox15 0.034 0.036 0.034 13 2.15 ± 0.05
HEK-293 ACRP30 control 0.031 0.031 0.032 1.94 ± 0.04
+ cdkl3 0.037 0.037 0.035 16 2.01 ± 0.02
+ cox15 0.036 0.035 0.036 14 2.10 ± 0.06
CHO control 0.033 0.034 0.034 1.95 ± 0.01
+ cdkl3 0.036 0.037 0.037 9 2.04 ± 0.02
+ cox15 0.036 0.035 0.035 5 2.09 ± 0.03
MDCK control 0.029 0.030 0.030 1.12 ± 0.04
+ cdkl3 0.030 0.029 0.030 0 1.10 ± 0.02
+ cox15 0.028 0.029 0.028 -5 1.08 ± 0.07
Western blot analysis for several different cell lines indicating  relative expression levels Figure 3
Western blot analysis for several different cell lines indicating 
relative expression levels. These cells were derived from 3 
different colonies that had already been screened and 
selected for expression of the transfected plasmid. At the 
time of analysis, these cells had been grown for over 6 days, 
post-transfection. The control cells were transfected with 
blank plasmids. 1 – HeLa 2 – HEK-293 3 – CHO
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Results of flow cytometric analysis; cell count vs. fluorescence Figure 4
Results of flow cytometric analysis; cell count vs. fluorescence. In each image the first peak (also the largest peak) indicates cells 
in the G0/G1 phases whereas the second, smaller peak indicates cells in the G2/M phases. In between these two peaks are cells 
in the S phase. The percentages of cells in each phase are shown along side each figure.
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To investigate the potential effects of enhanced expression
of either cdkl3 or cox15 on protein production in HEK-293
cells constitutively secreting recombinant adipocyte com-
plement-related protein of 30 kDa (acrp30); HEK-293
ACRP30 were transfected with plasmids containing either
cox15 or cdkl3. The cells were plated in T-flasks at an equiv-
alent seeding density. The total protein production levels
in ng/mL were measured in each flask along with the pro-
ductivities of acrp30 on a per cell basis, shown in Table 4.
Cells were assayed during the exponential growth phase
and not during the stationary phase, therefore the cell
densities listed were not maximum. The total protein lev-
els were increased by 20% in the cells transfected with
cdkl3 while an 11% increase was seen in cells transfected
with cox15. Specific production levels were higher in the
cells expressing either cdkl3 or cox15 relative to control
cells.
Discussion
Using clustering algorithms driven by gene ontology, dif-
ferentially expressed genes with functionalities relevant to
cell growth were identified when comparing slow grow-
ing, attached HeLa cells to fast growing, suspension HeLa
cells (Table 1). Two of the genes selected for further inves-
tigation, cdkl3 and cox15, were expressed at higher levels
in the suspension than in the attached HeLa cells, though
each gene was thought to relate to cellular growth in a dis-
tinct way. Previous studies suggest cdkl3 (cyclin-depend-
ent kinase like 3) is involved in cell cycle regulation/
progression, and cox15 (cytochrome c oxidase assembly
protein) is involved in energy metabolism [20,21].
The gene cdkl3 encodes a polypeptide of 455 amino acids
titled NKIAMRE [Swiss-Prot: Q8IVW4] that localizes in
the cytoplasm and is thought to be a component of a
kinase complex that phosphorylates the C-terminus of
RNA polymerase II [20,22,23]. Although, the precise func-
tionality of NKIAMRE remains unknown, sequence simi-
larities and the presence of several motifs together imply
membership to both the mitogen-activated protein kinase
(mapk) family and cyclin-dependent kinase (cdk) family
[20,24]. Both of these families are known to be involved
in signaling, cell cycle regulation, migration, and survival
[25].
As the gene name suggests, cdkl3  is most similar in
sequence to cyclin-dependent kinase 3 (cdk3); a gene that
encodes a kinase believed to be necessary for the G1-S
transition in mammalian cells [10,26]. The protein
encoded by cdkl3 also contains the highly conserved TXY
(Threonine-X-Tyrosine) motif found in the activation
loop domains of either a mapk or cdk [20,24]. In addi-
tion, two residues, a serine and a tyrosine, in subdomain
I closely resemble an adenosine triphosphate (ATP) bind-
ing domain and a negative regulation site typical of a cdk.
The protein's name itself, NKIAMRE signifies an amino
acid sequence thought to be a cyclin-binding domain also
found in a cdk [20,22]. Additionally, the catalytic domain
of NKIAMRE contains two highly conserved sequences
found in both serine/threonine and tyrosine protein
kinases [20,24]. High expression of nkiamre was detected
in two aggressive types of anaplastic large cell lymphoma
(ALCL) tumors when compared to peripheral blood lym-
phocytes [27]. This finding suggests the gene may also
play a role in pathogenesis and/or tumorigenesis.
The gene cdkl3 appears to act as either a cell cycle mimic
or regulator with several distinct functions including ATP
& nucleotide binding, kinase activity, and transferase
activity; all of which relate to regulation of the cell cycle
and control of cellular proliferation. The current study
supports these claims and suggests that cdkl3, like its
homolog cdk3, influences the cell cycle through observa-
tions of increased growth rates, reduced lag phases, and
greater protein production. The gene cdk3 is thought to be
rate-limiting for mammalian cell cycle progression [28].
Other studies have shown mammalian cells require cdk3
to exit the G0 and G1 phases as well as enter the S phase
[29,30]. These observations are also supported by the
present work through flow cytometry experiments that
indicated cells with an insert of cdkl3 were able to transi-
tion from the G0/G1 phases to the S phase faster than cells
without the insert.
Table 4: ELISA results for HEK-293 ACRP30 cells with and without gene inserts. The results shown are from 1 of 3 different runs 
performed, but are representative of all 3 runs
Cell line Viable cell density (106 cells/mL) Total protein production (ng) Average specific protein 
production ( )
control with plasmid 1.24 ± 0.01 1580 ± 130 1.27 × 10-3
+ cdkl3 1.40 ± 0.02 1900 ± 160 1.36 × 10-3
+ cox15 1.31 ± 0.03 1750 ± 190 1.34 × 10-3
Note: Each cDNA slide analyzed had at least 3 spots for each of the genes listed above. Analysis of 4 slides translated to a total of at least 12 ratios 
for each gene. Both the maximum and the minimum expression ratios per gene were determined from these 12 ratios (i.e. sample size).
ng mL
cells
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The human gene cox15  could relate to cellular growth
from the perspective of energy metabolism (i.e. cells
growing faster have greater energy demands). It encodes a
cytochrome c oxidase (COX) assembly protein referred to
as COX15 [Swiss-Prot: Q7KZN9] which localizes in the
mitochondrial inner membrane [31,32]. Significant
expression of cox15 has been observed in tissues with high
oxidative phosphorylation demands such as muscle,
heart, and brain [21,32].
Acting as the terminal enzyme of the respiratory chain,
COX is responsible for the transfer of electrons to molec-
ular oxygen, contributing to the generation of ATP via the
proton motive force [31,33]. COX15 is one of several
accessory proteins not part of the overall complex, but rel-
evant to the structure, synthesis, and processing of COX
[32,34]. Because COX is a large and intricate complex that
is continually being used, assembly proteins are also
thought to regulate its activity [32,35]. COX is thought to
be one of the rate-controlling steps of oxidative phospho-
rylation [36]. Together, these ideas suggest higher expres-
sion of cox15 could improve the efficiency of respiration.
Support for this can be found in the present study in that
cells with an insert of cox15  grew faster and produced
more recombinant protein (acrp30) than cells without
the insert.
Previous studies have shown COX15 is involved in the
synthesis of heme a, a compound believed to be critical to
energy conservation during oxygen reduction by COX
[33,37,38]. In fact, defects in the cox15 gene have resulted
in heme a deficiencies whereas defects in COX function
have lead to the onset of degenerative diseases such as
Leigh syndrome and encephalohepatopathy [21,32,35].
To date, only a few cases of these diseases have been the
result of a cox15 mutation; and in those select cases the
mutations were heterogeneous suggesting the loss of func-
tional COX15 may be fatal [21,34]. It has been proposed
that compounds like heme a when bound to proteins, can
facilitate the removal of damaging and apoptosis-trigger-
ing oxygen radicals [39,40]. These observations and pro-
posals suggest that higher cox15  expression might
counteract apoptosis, bolstering cell viability. This notion
is consistent with findings of the present study where
insertion of cox15 resulted in higher viable cell densities
than control cells.
The present study has shown the value of comparing fast
growing, suspension cells with the slow growing, attached
cells using microarrays to uncover genes that may contrib-
ute to the enhanced cell growth and improved survival of
attached HeLa cells. Two genes were found relevant to
enhanced cellular growth and increased viabilities; cdkl3
and  cox15. The proposed functions for these genes,
obtained from previous studies, are in agreement with the
changes that were observed when over-expressed in sev-
eral mammalian cell lines. The ability to control the cell
cycle and apoptosis can be useful in cell engineering for
biotechnology applications by providing greater cell mass
and improved yields of recombinant protein [1,3]. The
comparative physiology studies shown here, provide a
useful tool for identifying genes that may serve critical
roles in cell growth and other cellular functions. In the
present work, a handful of genes were investigated sepa-
rately, but the potential of this approach (using genomics
tools to engineer cell lines) may rely on being able to
modulate the expression of many genes simultaneously,
rather than individual genes. As such, the present study
represents an initial step attempting to directly control cel-
lular features with specific objectives in mind.
Methods
1. Bioreactor setup and sampling
The two HeLa cell lines, attached and suspension were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA) (Catalog Nos. CCL-2 and CCL-2.2,
respectively). Each cell line was grown in a BioFlo 3000
bioreactor (New Brunswick Scientific Co., Edison, NJ)
with a working volume of 1.5 L. Both cells lines were
grown concurrently. Runs were conducted for up to 7 days
after inoculation with constant sampling to characterize
growth parameters. Three different runs were carried out
for each cell line. The media used was DMEM (Biosource
International, Camarillo, CA) supplemented with 10%
FBS (Biosource International, Camarillo, CA). The
attached HeLa cells were grown on Cytodex 3 (Amersham
Biosciences, Piscataway, NJ) microcarriers. Each reactor
was seeded with 2.0 × 105 cells/mL [41,42]. Cells used to
seed the bioreactors were synchronized using serum dep-
rivation for 24 hours [6,15].
Each bioreactor was sampled at regular intervals to test
media composition (i.e. pH, Glucose, Lactate), cell viabil-
ity, and cell density. Each bioreactor was sampled for
microarray analysis at the same time corresponding to dif-
ferent phases of growth under batch conditions. Samples
were placed in 2 mL RNase/DNase-free micro tubes
(Marsh Biomediacal Products, Rochester, NY), combined
with TRIzol reagent (Invitrogen, Carlsbad, CA) and stored
at -80°C.
2. RNA isolation and sample preparation
Total RNA was purified from samples using an Invitrogen
kit (Micro-to-Midi Total RNA Purification System) and
quantified using a spectrophotometer, GeneQuant Pro
(Biochrom Ltd, Cambridge, UK). Absorbance values at
260 nm and the other at 280 nm were determined. The
quality of RNA was determined by the ratio of these num-
bers (A260/280). Only samples with an A260/280 of at least
1.8 were subsequently used for microarray analysis [15].BMC Biotechnology 2007, 7:71 http://www.biomedcentral.com/1472-6750/7/71
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Each sample, consisting of approximately 10 µg of total
RNA, was reverse transcribed, labeled, and prepared for
microarray hybridization using a protocol from The Insti-
tute for Genomic Research (TIGR) in Rockville, MD:
"Aminoallyl labeling of RNA for Microarrays" (SOP #
M004, Rev. 2) with an effective date of 3/4/2002.
3. cDNA microarray analysis
Microscope slides (Corning, Corning, NY) were printed
with a set of 32,448 spots corresponding to approximately
14,000 unique genes by TIGR (Rockville, MD) using an
array fabricator (Intelligent Automation, Rockville, MD).
Microarray preparation and hybridization were per-
formed using a protocol "Microarray labeled probe
hybridization" (SOP # M005, Rev. 3) available from TIGR
with an effective date of 9/11/2002. After washing and
drying, each slide was ready for scanning and image anal-
ysis using a GenePix 4000B (Molecular Devices Corpora-
tion, Sunnyvale, CA). Both technical and biological
replicates were included in the microarray experiments.
To ensure proper labeling efficiency the dyes for half of
the arrays were swapped [13,15,43].
Acuity software (Molecular Devices Corporation, Sunny-
vale, CA) was used to analysis the data starting with total
intensity normalization [13]. Additional steps were taken
to filter the data, removing spots with either poor signal
quality or genes with highly variable (i.e. inconsistent)
expression ratios [43]. The expression ratio for a gene, as
referred to in the present study, is defined as the test sam-
ple (suspension cell line) intensity divided by the control
sample (attached cell line) intensity. An expression ratio
of unity indicates equal hybridization between the two
samples being assayed whereas expression ratios above or
below 1.0 are referred to as being upregulated or downreg-
ulated, respectively [14].
The clustering algorithms applied to the data included:
self-organizing maps (SOMs), principle component anal-
ysis (PCA), and hierarchical clustering [14]. Genes clus-
tered together were probed to identify subsets of genes
with relevance to cellular growth (i.e. cell cycle regulation,
apoptosis, and/or signal transduction). The most differen-
tially expressed were then identified and evaluated based
on their known or proposed functionalities as indicated
in the literature [13,15].
Microarray results were verified by performing reverse
transcription-polymerase chain reaction (RT-PCR) experi-
ments. The protocols used were provided by Applied Bio-
systems (4333458, Rev. B & 4335626, Rev. C, both dated
05/2004). Each gene was assayed three times through two
separate experiments to establish greater statistical signif-
icance.
4. Enhanced expression of genes in various cell lines
Sequencing information for both cdkl3 and cox15 were
obtained using two public online databases; Harvester
(European Molecular Biology Laboratory, Heidelberg,
Germany) and GenBank (National Institutes of Health,
Bethesda, MD) [16,17]. For each gene, a plasmid contain-
ing the full-length cDNA was purchased from GeneCo-
poeia (Germantown, MD). Each plasmid also contained
the neomycin gene, conferring resistance to the com-
pound geneticin (Invitrogen, Carlsbad, CA). This resist-
ance allowed for the selection of clones expressing the
plasmid in the mammalian cell lines examined [5,10]. In
subsequent experiments, cells transfected with empty
plasmids (i.e. plasmids containing the neomycin gene
and other components but neither genes of interest, cdkl3
or cox15) served as the control.
To check gene and protein sequence homologies the Basic
Local Alignment Search Tool (BLAST) provided by the
National Center for Biotechnology Information (NCBI)
(Bethesda, MD) was used. Based on these results, several
cell lines were selected for investigation. Each of the fol-
lowing cell lines was purchased from ATCC (Manassas,
VA): HEK-293 (Catalog No. CRL-1573), CHO (Catalog
No. CCL-61), and MDCK (Catalog No. CCL-34). Another
cell line, HEK-293 ACRP30, was also studied because it
constitutively expresses acrp30 for which an enzyme-
linked immunosorbent assay (ELISA) is available [44,45].
This cell line was included in subsequent studies to evalu-
ate the impact of cdkl3 and cox15 on protein production.
Both HEK-293 cell lines were grown in DMEM (Biosource
International, Camarillo, CA) with 10% FBS (Biosource
International, Camarillo, CA). The media used with the
CHO cells was F-12K (ATCC, Manassas, VA) supple-
mented with 10% FBS (ATCC, Manassas, VA). The MDCK
cells were grown in EMEM (ATCC, Manassas, VA) supple-
mented with 10% FBS (ATCC, Manassas, VA). All of these
cell lines were grown in an incubator (Thermo Scientific,
Waltham, MA) set at 37°C and 5% CO2. In addition, all
of the cell lines were dissociated using a trypsin-EDTA
solution (ATCC, Manassas, VA).
Once several different cell lines were selected for analysis,
subsequent transfections were performed using manufac-
turer provided protocols packaged with each transfecting
agent. For the attached HeLa cells and the HEK-293 cell
lines (HEK-293 and HEK-293 ACRP30), the transfecting
agent used was Lipofectamine 2000 (Invitrogen,
Carlsbad, CA). In contrast, the transfecting agent used for
the suspension HeLa cells and the CHO cells was Lipo-
fectamine LTX (Invitrogen, Carlsbad, CA). And for the
MDCK cells, Optifect (Invitrogen, Carlsbad, CA) was the
transfecting agent used. The transfecting agents were
selected based on consultation with the manufacturer,
Invitrogen (Carlsbad, CA) in order to maintain consistentBMC Biotechnology 2007, 7:71 http://www.biomedcentral.com/1472-6750/7/71
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transfection efficiency levels between cell lines and have
reproducible results.
Transfections were performed in 24-well plates (Corning,
Corning, NY). Within 24 hours following the transfection
the media was replaced with complete media. Once the
cells had recovered, usually after 48 hours, geneticin was
added to a final concentration of 750 µg/mL based on a
prior kill curves (data not shown). Over several days, as
media was periodically replaced, colonies began to form.
Individual colonies were isolated and moved into 96-well
plates (Corning, Corning, NY). Upon reaching conflu-
ency, each well was expanded sequentially into 24, 12,
and 6-well plates (Corning, Corning, NY) before being
counted and screened for expression based on western
blot analysis. Physiological changes, post-transfection,
were also observed using a DM IRB microscope and
attached camera (Leica Camera, Allendale, NJ).
Western blotting was conducted to verify translation of
gene inserts via transfected plasmids. Protocols for this
method were made available by the manufacturers of the
primary antibodies for COX15 (Abnova, Taipei City, Tai-
wan) and CDKL3 (Abcam, Cambridge, MA). Briefly, cell
lysate samples were prepared from a population of cells
that were counted and assayed for viability. These samples
were diluted with reducing sample buffer and separated
using 4–20% Tris-Glycine gels (Invitrogen, Carlsbad, CA).
Proteins were transferred to nitrocellulose membranes
(Invitrogen, Carlsbad, CA) and blocked with blotting
grade blocker, non-fat dry milk (Bio-Rad, Hercules, CA)
for 1 hour. Membranes were then incubated with the pri-
mary antibodies at a dilution of 1:500 for 1 hour followed
by incubation with secondary antibodies (HRP-conju-
gated secondary antibodies) for another hour. Incubation
with a color development agent (KPL, Gaithersburg, MD)
allowed visualization of the blots which were then
scanned.
Following clone screening, cells expressing the desired
plasmid were expanded successively into 6-well plates and
25 cm2 T-flasks. For growth comparisons, 75 cm2 T-flasks
(Corning, Corning, NY) and 250 mL spinner flasks
(Bellco Glass, Vineland, NJ) were seeded and monitored
for pH (Radiometer Analytical SAS, Lyon, France), cell via-
bility & density (Cedex HiRes, Innovatis, Malvern, PA),
and metabolite concentrations (YSI, Yellow Springs, OH)
[41,42]. Cell counting was performed two different ways;
using a cell counter (Cedex HiRes) and using a hemocy-
tometer. In both cases, duplicates of each sample were
assayed. The Cedex HiRes was used as instructed by the
manufacturer. Samples counted manually were diluted
1:1 with tryphan blue and counted on a hemocytometer.
Variation between duplicates and between counting
methods were calculated to be = 2.5% In conjunction
with the spinner flasks, Cytodex 3 microcarriers (GE
Healthcare, Piscataway, NJ) were used for the cell lines
studied [13]. Cells used for seeding were synchronized
using the mitotic shake-off method [6,9].
5. Flow cytometry and ELISA
Cells grown in 162 cm2 T-flasks were sampled at different
points along their respective growth curves for analysis
using a flow cytometer. Samples were taken during the
early, middle, and late exponential growth phase, follow-
ing synchronization by the mitotic shake-off method
[6,9]. Flow cytometry experiments were performed using
a CyAn LX flow cytometer (DakoCytomation, Fort Col-
lins, CO). Cells were fixed with ethanol and stained with
propidium iodide (Becton Dickinson, Franklin Lakes, NJ)
at a concentration between 0.5 – 1.0 × 106 cells/mL [46].
Summit software (DakoCytomation, Fort Collins, CO)
was used to capture data generated by the sampled cells
such as the level of light scattering and fluorescence. In
contrast, Modfit software (Molsoft, La Jolla, CA) was used
to identify varying stages of the cell cycle and calculate the
percentages of cells in each stage.
To quantify the amount of acrp30 secreted by HEK-293
ACRP30 cells an ELISA was performed using a kit pro-
duced by R&D Systems (Catalog No. MRP300, Minneap-
olis, MN). A microplate spectrophotometer (SpectraMax
190, Molecular Devices, Sunnyvale, CA) was used to
quantify the amount of protein present in the samples.
Samples were run at varying dilutions to establish the
minimum dilution level necessary to obtain values that
fall within the standard curve. This value was determined
to 1:4,000 (data not shown).
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